Daniel P. O'Day - 10 Mar 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Role
Chairman & CEO, Director
Signature
/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day
Issuer symbol
GILD
Transactions as of
10 Mar 2025
Transactions value $
-$1,363,387
Form type
4
Filing time
12 Mar 2025, 19:12:43 UTC
Previous filing
06 Feb 2025
Next filing
02 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GILD Common Stock Options Exercise +24K +3.89% 642K 10 Mar 2025 Direct F1
transaction GILD Common Stock Tax liability -$1.36M -11.6K -1.81% $117.21 630K 10 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GILD Restricted Stock Unit Options Exercise -24K -22.89% 81K 10 Mar 2025 Common Stock 24K Direct F1, F2
transaction GILD Non-qualified Stock Option (Right to Buy) Award $0 +170K $0.00 170K 10 Mar 2025 Common Stock 170K $117.21 Direct F3
transaction GILD Restricted Stock Unit Award +38.4K +47.43% 119K 10 Mar 2025 Common Stock 38.4K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3 The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.